Oncternal And SpringWorks Among Early ASCO Winners And Losers

SpringWorks Declines Despite Positive Results

 
• By Andrew McConaghie

While the big pharma names dominate the ASCO cancer congress, it is also a chance to shine for emerging small-to-medium biopharma companies.

Nasdaq
Many NASDAQ-listed biotech companies are in need of a share price bounce, which are hard to come by in the current market. • Source: Alamy

More from Anticancer

More from Therapy Areas